89bio Inc (ETNB)
9.00
+0.03
(+0.33%)
USD |
NASDAQ |
May 20, 14:05
89bio Free Cash Flow: -138.82M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -138.82M |
| December 31, 2023 | -129.19M |
| September 30, 2023 | -121.99M |
| June 30, 2023 | -106.44M |
| March 31, 2023 | -86.83M |
| December 31, 2022 | -81.10M |
| September 30, 2022 | -82.27M |
| June 30, 2022 | -80.92M |
| March 31, 2022 | -86.21M |
| Date | Value |
|---|---|
| December 31, 2021 | -76.84M |
| September 30, 2021 | -62.61M |
| June 30, 2021 | -62.10M |
| March 31, 2021 | -53.54M |
| December 31, 2020 | -46.37M |
| September 30, 2020 | -43.58M |
| June 30, 2020 | -36.83M |
| March 31, 2020 | -29.24M |
| December 31, 2019 | -25.60M |
Free Cash Flow Range, Past 5 Years
-138.82M
Minimum
Mar 2024
-25.60M
Maximum
Dec 2019
-75.03M
Average
-78.88M
Median
Free Cash Flow Benchmarks
| Akero Therapeutics Inc | -155.88M |
| Madrigal Pharmaceuticals Inc | -391.12M |
| Viking Therapeutics Inc | -54.87M |
| Galectin Therapeutics Inc | -34.28M |
| Terns Pharmaceuticals Inc | -75.89M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -39.72M |
| Cash from Investing (Quarterly) | -79.90M |
| Cash from Financing (Quarterly) | 21.03M |
| Free Cash Flow Per Share (Quarterly) | -0.4144 |
| Free Cash Flow Yield | -18.86% |